Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Inclusion Criteria: * 1\. Age 18 to 70 years old, gender is not limited; * 2\. Hematological tumors, including but not limited to B-cell lymphoma, multiple myeloma, B Cell acute leukemia, T-cell lymphoma, T-cell acute leukemia, and patients with disease progression, relapse, or ineligibility for standard regimen therapy after standard regimen therapy ; * 3\. Patients without serious organic lesions in the heart, lung, liver and kidney (LVEF (left ventricular ejection fraction \>=50%; total bilirubin \<=1.5×ULN; alanine aminotransferase (ALT) \<=1.5×ULN; aspartate aminotransferase); (AST) \<=1.5×ULN (; serum creatinine\<=1.5×ULN or CCr\>40mL/min); * 4\. Those without severe coagulation dysfunction (PT\<=1.5×ULN, APTT\<=1.5×ULN, TT\<=1.5×ULN and FIB\>=1.0 g/L); * 5\. Patients without severe hematopoietic dysfunction (absolute neutrophil value\>=1.5×109/L, platelets \>=75×109/L, hemoglobin\>=80g/L), and no platelet, red blood cell, hemoglobin; * 6\. Patients received at least 4 weeks or more than 5 half-lives after the last antitumor treatment (chemotherapy, radiotherapy, biological therapy or immunotherapy) before enrollment; * 7\. Expected survival time\>= 12 weeks; * 8\. ECOG score \<=2 points; * 9\. Those who agree to participate in this study and sign the informed consent form. Exclusion Criteria: * 1\. The toxicity of previous anticancer therapy has not recovered to grade I or below, or has not fully recovered from previous surgery; * 2\. Those with severe heart, lung, liver, kidney, digestive system diseases and chronic diseases of vital organs * 3\. Pregnant or breastfeeding female patients, fertile female/male patients who refuse to use contraceptive measures during the trial; * 4\. A history of acute myocardial infarction, congestive heart failure, unstable angina pectoris, or stroke within 6 months before enrollment; * 5\. Patients with impaired cardiac function (ejection fraction \<45% detected by echocardiography or complete left bundle branch block with ECG ST segment downshift \>1 mm or T wave inversion in two or more channels; congenital ventricular or Atrial arrhythmia, clinically significant tachycardia (\>100 beats/min), bradycardia (\<50 beats/min), ECG QTc \>450 ms (men), QTc \>480 ms (women), or clinically significant cardiac Diseases (such as unstable angina, congestive heart failure, myocardial infarction within 6 months), etc.; * 6\. Those with central nervous system lymphoma/leukemia or mental disorders; * 7\. Have a history of organ transplantation; * 8\. Those with severe active infection; * 9\. Known severe hypersensitivity to the test drug and its excipients or HDAC inhibitors; * 10\. HCV antigen or antibody positive, HIV antigen or antibody positive, HBsAg positive, HBcAb positive and peripheral blood HBV DNA titer detection \>=1×103 IU/mL; * 11\. Alcohol dependence or drug abusers; * 12\. Those who have participated in clinical trials of other drugs within the past 1 month; * 13\. The researchers conclud that there are other factors that are not suitable for participating in the trial.